# Mentari Therapeutics, Inc.

**MTRI**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001728328

# None

**No letter**

4 of 13 inputs computable; 7 are required, with a score in every sleeve

| Scoreboard | |
|---|---|
| **Reliability** | 0.76 AUC<br>filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025 |
| **Peer failure rate** | 0.60% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | under $12.5M assets<br>total assets $3.0M |
| **Standard universe** | outside<br>revenue above $1M and assets above $10M |
| **Warnings** | dilution, thin data, distress<br>not computable: short runway, fortress balance sheet |
| **Inputs computable** | 4 of 13 |
| **Graded from** | filings received through Sep 9, 2026<br>74 days before the rescan; latest periodic filing 10-Q received Nov 3, 2026 |
| **Last close** | $14.76<br>2026-11-20; market equity $8.1M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2026 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Sep 9, 2026*

All dollar amounts stated herein are in U.S. dollars unless specified otherwise. We are a pharmaceutical drug development company with a pipeline of proprietary small molecule drug candidates that are preferential signaling ligands of the endogenous CB1 and CB2 receptors as well as other receptor targets linked to human disease. CB1 and CB2 receptors are each part of the endocannabinoid system that is found throughout the human body and is responsible for many homeostatic functions. CB1 receptors are primarily located in the brain and central nervous system, while CB2 receptors are involved in modulating neuroinflammation and immune responses.

## The thirteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 8.5** | | | | | | |
| Gross profitability | not computable | 32.8% | | | | |

*latest aligned inputs end 2025-06-30; latest annual assets end 2026-06-30*

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| Return on invested capital | not computable | 9.6% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Accruals ratio | (42.1%) | (6.7%) | | 8.5 | 756 | 2026-06-30 |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 4* | | | | | | |
| **Solvency, sleeve percentile 84.7** | | | | | | |
| Altman Z double-prime | not computable | 0.31 | | | | |
| *latest aligned inputs end 2023-06-30; latest annual assets end 2026-06-30* | | | | | | |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Interest coverage | not computable | (3.61x) | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Current ratio | 1.37x | 2.68x | | 84.7 | 781 | 2026-06-30 |
| **Growth and financing, sleeve percentile 91.3** | | | | | | |
| Revenue growth, three-year compound | not computable | 9.6% | | | | |
| *latest aligned inputs end 2025-06-30; latest annual assets end 2026-06-30* | | | | | | |
| Free cash flow growth, three-year compound | not computable | 11.1% | | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | | |
| Reinvestment rate | not computable | 33.9% | | | | |
| *pretax income must exceed the validity floor and imply a 0%-100% tax rate* | | | | | | |
| Asset growth, three years | (40.1%) | 3.2% | | 96.7 | 663 | 2026-06-30 |
| Net share issuance, one year | 130.4% | 1.6% | | 85.9 | 626 | 2026-09-02 |

## Warnings

*3 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Dilution | split-adjusted year-over-year share growth is 130.4% |
| Thin data | 4 of 13 grade factors are computable; minimum is 7 |
| Distress | CHS probability 100.000000%; universe top-decile threshold 2.175581% |

## What the price implies

*at the 2026-11-20 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (27.7%) | (1.7%) | 32 |
| Distance from 52-week high | (26.0%) | (33.0%) | 57 |
| EBIT to enterprise value | not computable | 0.5% | |
| Free cash flow yield | (86.6%) | 0.6% | 9 |
| Book value to price | (0.15) | 0.29 | 6 |
| Sales to price | 0.61 | 0.38 | 64 |
| Composite equity issuance, five years | 568.0% | 13.5% | 98 |
| Relative strength against the sector, log excess return | (0.50) | (0.19) | 32 |
| Twelve-month failure probability, CHS model | 100.00% | 0.06% | 90 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2026-06-30** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | n/a |
| Operating cash flow, four quarters | n/a |
| Months of runway | not finite |
| Days since last periodic filing | 19 (10-Q received Nov 3, 2026) |
| Median daily dollar volume, 63 sessions | $76,323 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | gross profit | us-gaap:GrossProfit | $1.7M | 2025-06-30 | 2025-09-23 | 10-K | 25-090210 |
| 2 | assets | us-gaap:Assets | $15.6M | 2025-06-30 | 2026-09-09 | 10-K | 26-098419 |
| 3 | net income | us-gaap:NetIncomeLoss | -$12.6M | 2026-06-30 | 2026-09-09 | 10-K | 26-098419 |
| 4 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$8.6M | 2026-06-30 | 2026-09-09 | 10-K | 26-098419 |
| 5 | assets | us-gaap:Assets | $3.0M | 2026-06-30 | 2026-09-09 | 10-K | 26-098419 |
| 6 | current assets | us-gaap:AssetsCurrent | $11.3M | 2023-06-30 | 2024-09-30 | 10-K | 24-082843 |
| 7 | current liabilities | us-gaap:LiabilitiesCurrent | $2.0M | 2023-06-30 | 2024-09-30 | 10-K | 24-082843 |
| 8 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$101.4M | 2023-06-30 | 2024-09-30 | 10-K | 24-082843 |
| 9 | operating income | us-gaap:OperatingIncomeLoss | -$7.9M | 2023-06-30 | 2023-09-29 | 10-K | 23-080842 |
| 10 | book equity | us-gaap:StockholdersEquity | $12.1M | 2023-06-30 | 2025-09-23 | 10-K | 25-090210 |
| 11 | assets | us-gaap:Assets | $14.1M | 2023-06-30 | 2024-09-30 | 10-K | 24-082843 |
| 12 | liabilities | us-gaap:Liabilities | $2.0M | 2023-06-30 | 2024-09-30 | 10-K | 24-082843 |
| 13 | current assets | us-gaap:AssetsCurrent | $2.7M | 2026-06-30 | 2026-09-09 | 10-K | 26-098419 |
| 14 | current liabilities | us-gaap:LiabilitiesCurrent | $2.0M | 2026-06-30 | 2026-09-09 | 10-K | 26-098419 |
| 15 | revenue | us-gaap:Revenues | $4.9M | 2025-06-30 | 2025-09-23 | 10-K | 25-090210 |
| 16 | revenue | us-gaap:Revenues | $4.6M | 2024-06-30 | 2025-09-23 | 10-K | 25-090210 |
| 17 | revenue | us-gaap:Revenues | $4.1M | 2023-06-30 | 2024-09-30 | 10-K | 24-082843 |
| 18 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $1.4M | 2022-06-30 | 2022-09-23 | 10-K | 22-058355 |
| 19 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$7.0M | 2024-06-30 | 2025-09-23 | 10-K | 25-090210 |
| 20 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $9,293 | 2024-06-30 | 2025-09-23 | 10-K | 25-090210 |
| 21 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$7.3M | 2023-06-30 | 2024-09-30 | 10-K | 24-082843 |
| 22 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $160,014 | 2023-06-30 | 2024-09-30 | 10-K | 24-082843 |
| 23 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$15.6M | 2022-06-30 | 2023-09-29 | 10-K | 23-080842 |
| 24 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $39,108 | 2022-06-30 | 2023-09-29 | 10-K | 23-080842 |
| 25 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$9.8M | 2021-06-30 | 2022-09-23 | 10-K | 22-058355 |
| 26 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $1,725 | 2021-06-30 | 2022-09-23 | 10-K | 22-058355 |
| 27 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $202,249 | 2023-06-30 | 2024-09-30 | 10-K | 24-082843 |
| 28 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$7.9M | 2023-06-30 | 2024-09-30 | 10-K | 24-082843 |
| 29 | income tax | us-gaap:IncomeTaxExpenseBenefit | $13,100 | 2023-06-30 | 2024-09-30 | 10-K | 24-082843 |
| 30 | current assets | us-gaap:AssetsCurrent | $9.6M | 2022-06-30 | 2023-09-29 | 10-K | 23-080842 |
| 31 | current liabilities | us-gaap:LiabilitiesCurrent | $3.3M | 2022-06-30 | 2023-09-29 | 10-K | 23-080842 |
| 32 | assets | us-gaap:Assets | $11.8M | 2024-06-30 | 2025-09-23 | 10-K | 25-090210 |
| 33 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 5,493,735 | 2026-09-02 | 2026-09-09 | 10-K | 26-098419 |
| 34 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 2,384,186 | 2025-09-17 | 2025-10-24 | 10-K/A | 25-102157 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.